Pfizer-BioNTech vaccine offers over 95 percent protection against COVID-19, says largest real-world study
The global use of the Pfizer/BioNTech vaccine is limited by supply issues, high costs, and ultra-cold chain storage requirements.
By doing so, around 80 percent of Canadians over the age of 16 will receive a single dose by the end of June with the expected supply of Pfizer-BioNTech and Moderna vaccines
Catching COVID-19 from surfaces is very unlikely, maybe we should ease up on the constant disinfecting
This isn’t to say surface transmission isn’t possible and that we should disregard it completely but, we should acknowledge the threat is relatively small.